Research Article
Analysis of Motor Complication and Relative Factors in a Cohort of Chinese Patients with Parkinson’s Disease
Table 1
Demographic, clinical, and medical characteristics for our subjects.
| | Characteristics | Value |
| | Gender (male/female) | 89/77 | | Age (years, mean ± SD) | 65.8 ± 9.11 | | Onset age (years, mean ± SD) | 60.83 ± 9.91 | | Disease duration (years, mean ± SD) | 4.96 ± 3.90 | | Clinical phenotypes (n, %) | | | Tremor | 89 (53.61) | | Bradykinesia-rigidity | 77 (46.39) | | Modified Hoehn–Yahr stages (n, %) | | | 1 | 18 (10.84) | | 1.5 | 33 (19.88) | | 2 | 56 (33.73) | | 2.5 | 20 (12.05) | | 3 | 27 (16.27) | | 4 | 12 (7.23) | | UPDRS scores (mean ± SD) | 39.93 ± 18.80 | | UPDRS III scores (mean ± SD) | 22.19 ± 11.83 | | Daily levodopa dosages (mg) | 474.20 ± 268.76 | | LEDD (mg/d, mean ± SD) | 457.48 ± 386.00 | | L-dopa duration (years, mean ± SD) | 2.93 ± 3.68 | | Medications (n, %) | | | Levodopa-benserazide | 135 (81.33) | | Levodopa-carbidopa | 11 (6.63) | | Dopamine agonist | 92 (55.42) | | MAO-B inhibitor | 44 (26.51) | | COMT inhibitor | 9 (5.42) | | Anticholinergic | 26 (15.66) | | Amantadine | 16 (9.64) |
|
|
Abbreviations: SD, standard deviation; UPDRS: unified Parkinson disease rating scale; LEDD: levodopa equivalent daily dose; MAO: monoamine oxidase; and COMT: catechol-o-methyltransferase.
|
